IP Verse

Crystalline Ingenol Mebutate - EP2558435

The patent EP2558435 was granted to LEO Pharma on Jun 7, 2017. The application was originally filed on Apr 18, 2011 under application number EP11731076A. The patent is currently recorded with a legal status of "Revoked".

EP2558435

LEO PHARMA
Application Number
EP11731076A
Filing Date
Apr 18, 2011
Status
Revoked
Jun 14, 2019
Grant Date
Jun 7, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 7, 2018FRKELLYADMISSIBLE
TEVA PHARMACEUTICALSMar 7, 2018D YOUNGADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1015413
DESCRIPTIONWO2007053912
DESCRIPTIONWO2007059584
DESCRIPTIONWO2007068963
DESCRIPTIONWO2008131491
INTERNATIONAL-SEARCH-REPORTWO2007053912
INTERNATIONAL-SEARCH-REPORTWO2007059584
INTERNATIONAL-SEARCH-REPORTWO2008131491
OPPOSITIONWO2007053912
OPPOSITIONWO2007059584
OPPOSITIONWO2008131491

Non-Patent Literature (NPL) Citations (14) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Assessment Report Picate. International non-proprietary name: ingenol mebutate", European Medicines Agency, (20120000), pages 1 - 11, XP055470281-
OPPOSITION- "Assessment Report Picate. International non-proprietary name: ingenol mebutate", European Medicines Agency, Assessment Report, (20120920), pages 1 - 11, XP055470281-
OPPOSITION- "Crystallization", Pharmaceutics: The Science of Dosage Form Design, (20020000), page 142, XP055472752-
OPPOSITION- DSC curve for amorphous ingenol mebutate-
OPPOSITION- "LEO Pharma to Acquire Peplin for US $287.5m", LeoPharma A/S, (20090903), URL: http://www.leo-pharma.com/Home/LEO-Pharma/Media- centre/News/News-2009/2009-sep-03-LEO-Pharma-to-Acqu ire-Peplin-for-US$287.5m.aspx#, XP055472749-
OPPOSITION- M BAVIN, "Polymorphism in process development", Chemistry & Industry, (19890800), vol. 21, pages 527 - 529, XP001180136-
OPPOSITION- "Poster abstracts, Supplement to Journal of the American Academy of Dermatology", American Academy of Dermatology, (20090300), vol. 60, no. 3-
OPPOSITION- "Poster abstracts, Supplement to Journal of the American Academy of Dermatology", American Academy of Dermatology, (20100300), vol. 62, no. 3-
OPPOSITION- "PRODUCT MONORAPH "PICATO" INGENOL mebutate", Leo Pharma, (20130000), pages 1 - 2,14, XP055470361-
OPPOSITION- SWANSON N, "P105 Multicenter, randomized, parallel-group, double-blind, vehicle-controlled study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.05% in patients with actinic keratoses on nonhead locations", American Academy of Dermatology, 68th Annual Meeting, (20100301), vol. 62, no. 3, XP026902428
OPPOSITION- SPENCER J, "P2913 Multicenter, randomized, double-blind, vehicle-controlled, dose-ranging study to evaluate the efficacy and safety of PEP005 (ingenol mebutate) gel 0.005%, 0.01% and 0.015% when used to treat actinic keratoses on the head", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, (20100300), page AB105, XP026902837
OPPOSITION- S BYRN et al., "Pharmaceutical solids: a strategic approach to regulatory consideration", Pharmaceutical Research, (19950700), vol. 12, no. 7, pages 945 - 954, XP000996386
OPPOSITION- SM OGBOURNE et al., "Proceedings of the First International Conference on PEP005", Anti-Cancer Drugs, (20070000), vol. 18, no. 3, pages 357 - 362, XP008124412
OPPOSITION- ERSVAER et al., "The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity", Toxins, (20100122), vol. 2, no. 1, pages 174 - 194, XP055395075

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents